

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q4 15-16	Q4 14-15	% Gr y-y	YTD 15-16	YTD 14-15	% Gr y-y
Home Markets	17,837	17,133	4.1%	72,125	63,053	14.4%
US Formulations	9,610	9,789	-1.8%	40,215	33,932	18.5%
India Formulations	7,674	6,797	12.9%	29,732	26,772	11.1%
Latin America Formulations	553	547	1.1%	2,177	2,348	-7.3%
Other Markets and Businesses	6,443	5,833	10.5%	24,474	23,524	4.0%
Europe Formulations	706	740	-4.6%	2,956	3,376	-12.4%
Emerging Markets Formulations	1,343	1,108	21.3%	4,760	4,058	17.3%
Consumer Wellness	1,169	1,114	5.0%	4,570	4,430	3.2%
Animal Health & Others	844	823	2.5%	3,199	3,217	-0.6%
APIs	922	870	6.0%	3,647	3,723	-2.0%
JVs and Alliances	1,459	1,178	23.8%	5,342	4,721	13.2%
Grand Total	24,280	22,967	5.7%	96,598	86,577	11.6%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q4 15-16	Q4 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
Other Operating Income	736	411	79.0%	3,682	1,542	138.8%
Export Incentive	351	72	387.4%	1,228	287	327.9%
Royalty Income	10	8	38.6%	179	390	-54.1%
Net Gain on foreign currency transactions and translation (Refer Note below)	46			352		
Others	328	331	-0.9%	1,923	865	122.2%

Note : There was a net loss of Rs. 22 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods in Q4 15-16. Thus, on aggregate level, there was a gain of Rs. 24 Mio. on operating transactions (above EBIDTA line) in Q4 15-16 vs loss of Rs. 358 Mio. in Q4 14-15. See details below for more clarity.

Rs. Mio.	Q4 15-16	Q4 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
Other Income	241	203	18.4%	941	554	69.9%
Interest & Dividend income	170	132	29.0%	623	413	50.9%
Profit on sale of investments	60	5	1161.8%	116	33	251.6%
Others	11	67	-84.1%	202	108	87.0%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q4 15-16	Q4 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
A. On operating transactions (above EBIDTA line)	-24	358	-106.7%	-721	284	-353.9%
a. Included in other income	-46			-352		
c. Included in cost of goods	22	190	-88.4%	-369	100	-469.0%
d. Included in other expenses		168	-100.0%		184	-100.0%
B. On Foreign Currency Borrowings (part of interest cost)	-36	42	-185.7%	23	66	-65.2%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	-60	400	-115.0%	-698	350	-299.4%

Details of R&D Expenses

Rs. Mio.	Q4 15-16	Q4 14-15	% Gr y-y	YTD 15- 16	YTD 14- 15	% Gr y-y
Total R&D Expenses	1,812	1,488	21.8%	7,594	5,606	35.5%

Consolidated Capex for Apr 15 - Mar 16

Rs. 9477
Mio.

R&D capex included in above for Apr 15 - Mar 16

Rs. 254
Mio.